Xuanzhu Biopharmaceutical Co., Ltd.
XuanZhu Biopharma is a clinical stage, biotechnology company wholly owned by Sihuan Pharmaceutical Holdings Group. We are focused on bringing to market first-in-class therapies for unmet and underserved patient populations. Our therapeutic areas include oncology and metabolic/liver diseases. The cornerstone of our oncology franchise is Birociclib (CDK 4/6i). We have seven programs in clinical development all of which we expect to launch within the next seven years with expected revenues reaching $400 M by 2025 and exceeding $1 B by 2030. XuanZhu has closed its Series A financing in August 2020, raising a total of ¥800 M (~ $118 M)